Please ensure Javascript is enabled for purposes of website accessibility

Why Catalyst Pharmaceuticals Is Getting Crushed Today

By George Budwell - May 7, 2019 at 12:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Catalyst's shares are in free fall today after the FDA's surprise approval of a rival LEMS medication.

What happened

Shares of Catalyst Pharmaceuticals (CPRX 2.02%) are in a tailspin this morning after news broke that the Food and Drug Administration (FDA) surprisingly approved Jacobus Pharma's Lambert-Eaton myasthenic syndrome (LEMS) drug, Ruzurgi, for patients between six to 17 years of age.

Although Catalyst's FDA-approved Firdapse is indicated for adult LEMS patients, doctors are free to prescribe Ruzurgi off-label for patients of any age, potentially setting up a head-to-head battle between the two for market share. As of 10:34 a.m. EDT, Catalyst's stock was down by a whopping 37% on over four times the average daily volume in the wake of this unexpected development.   

A man with his mouth open as if in shock while clasping his hand to his forehead. A downward trending graph in white is in the background.

Image source: Getty Images.

So what

With Firdapse's annual price tag coming in at an eye-popping $375,000 per patient and no competition in sight, Catalyst was set to reap the rewards from its first major FDA approval in a big way. In fact, the drugmaker's shares had already bolted higher earlier this year after Firdapse's initial script numbers came in well above expectations, thanks to little resistance from third-party payers across most of the United States.

This new rival, however, could upset the apple cart. Jacobus is likely to price its LEMS drug at a fraction of Firdapse. Although Catalyst can make the argument to insurance companies that only Firdapse is FDA-approved for adults, payers are almost certain to use Ruzurgi as leverage in future negotiations. 

Now what

Is this sell-off warranted? Yes. The heart of the matter is that Firdapse's premium pricing structure is now at serious risk. Insurance companies usually don't readily reimburse drugs for off-label use, but Ruzurgi should be priced in a manner that makes it far more palatable to payers than Firdapse.

Fortunately, Catalyst is set to report first-quarter earnings next Monday, May 13. This upcoming earnings report should give the company a friendly platform to tell its side of the story. Until then, investors might want to stand pat with this small-cap biotech.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Catalyst Pharmaceuticals, Inc. Stock Quote
Catalyst Pharmaceuticals, Inc.
$7.06 (2.02%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.